ClinicalTrials.gg
Enrolling by invitationNCT06746077INSPIRE CHILDUpdated Oct 29, 2026

Investigating Novel Strategies in Pediatric Immune Responses and Microbiome Environment: Comprehensive Lung Disease Investigation in Children.

An observational study in Lung Diseases, sponsored by Aarhus University Hospital. Enrolling by invitation at 1 site in Denmark. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Aarhus University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
0 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Lung Diseases with a site in Denmark — 16 open to participants now, 20 under way, 8 of them phase 3. Lung Diseases · Denmark.

Started
2024
with 4 others
Observational
9 of 43
4 open now
Primary completion
2027-12
later than 13 of 19 live
Registered
36th of 43
by date
Lead sponsor
1 of 43
Aarhus University Hospital

Among the 43 studies in Lung Diseases with a site in Denmark, this one is one of 5 that started in 2024, is one of 9 observational ones, reaches primary completion later than 13 of the 19 other live ones, and was the 36th registered.

Lung Diseases

1,159 studies on the registry are indexed under Lung Diseases; 181 are open to participants now.

Browse Lung Diseases studies →

Open to participants now

16 of the 43 studies in Lung Diseases with a site in Denmark are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 138 Lung Diseases studies recruiting now, 75 (54%) set no upper age limit and 28 (20%) stop at 75 or younger; 15 take children under 18; 26 take healthy volunteers.

This study: 0 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Lung Diseases with a site in Denmark, or all of them as a file.
02

Study summary

The INSPIRE CHILD-study is a clinical research project focused on understanding lung diseases in children. The study aims to explore how the presence of certain bacteria, immune responses, and inflammatory markers in the lungs are connected to different lung diseases in pediatric patients.

Background:

Lung diseases in children can have long-lasting effects on their health, not only during childhood but also as they grow into adults. However, the specific causes and mechanisms behind these diseases are not yet fully understood. The INSPIRE CHILD-study is designed to investigate whether children with various lung conditions have distinct differences in the types of bacteria, immune system activity, and inflammation in their lungs.

Hypothesis:

Different lung diseases in children are hypothesized to be associated with unique patterns of bacteria, immune responses, and inflammation in the lungs By studying these patterns, the investigators hope to gain new insights that could lead to better diagnostic tools and more personalized treatments for children suffering from lung diseases.

Children already scheduled to undergo bronchoscopy are included in the study. A small sample of fluid from the lungs is collected, and the sample is analyzed for bacteria, immune markers, and signs of inflammation. This research could pave the way for improved care and treatment for young patients with lung conditions.

03

Conditions studied

  • Lung Diseases

Keywords

  • Pediatric
  • Lung Disease
  • Microbiome
  • Cytokine
  • Inflammation
  • Immune Cell
  • Bacteria
  • Asthma
  • Coughing
  • Immunophenotype
  • Bronchiectasis
  • Bronchoscopy
  • BAL
  • Bronchoalveolar lavage
  • Diffuse Lung Disease
  • Interstitial Lung Disease
04

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Approximately 200 children/adolescents with lung disease undergo bronchoscopy yearly at Childrens Center for Pulmonary and Allergic diseases, Aarhus University Hospital. All patients are on clinical indication already scheduled for bronchoscopy and BAL. Participants are recruited from this group of patients if they comply with the inclusion/exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ranging from new-born to 17 years of age.
  • Diagnosed with or being assessed for a lung disease.
  • Possible to sample at least 2 ml of BAL-fluid besides the scheduled amount during the bronchoscopy.

Exclusion criteria

Exclusion Criteria:

  • Age older than 17 years.
  • Not undergoing diagnosis at Childrens Center for Pulmonary and Allergic diseases.
  • Failure to meet the requirement of being able to sample an additional 2 ml of BAL-fluid.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. Cytokines

    Legendplex assay for measuring cytokines in bronchoalveolar lavage fluid and plasma (e.g. IL-1-beta, IL-1RA, IL-2, IL-6, IL-8, IL-10, IL-17, IL-18, IL-33, IL-35, TGF-beta, TNF-alpha)

    Time frame: Day 0 (Subsequent to study inclusion)

  2. Immunophenotype

    Using flow cytometry to investigate immune cells: e.g. Neutrophils, Eosinophils, Monocytes, NK-cells, B-cells, CD4+-T-cells, CD8+-T-cells

    Time frame: Day 0 (Subsequent to study inclusion)

  3. Lung microbiome

    We seek to investigate whether it is feasible to map the microbiome, virome and mycobiome of the pediatric lung from BAL-fluid. The study will investigate and report findings of bioinformatics analysis.

    Time frame: Day 0 (Subsequent to study inclusion)

Secondary outcomes

  1. Concentration range for selected interleukins in BAL-fluid

    Time frame: Day 0 (Subsequent to study inclusion)

  2. Lung disease association

    Can we associate a specific profile of findings with a particular pediatric lung disease?

    Time frame: Through study completion, an average of 2 year

  3. Clinical symptoms

    2 weeks prior to date of inclusion/bronchoscopy, the subjects medical history is reviewed for the following: Characterization of cough Respiratory distress Functional limitations (due to respiratory distress) (acc. to age) Fever (temperature above 38.0 C) Breath sounds Urgent need for medication

    Time frame: 2 weeks prior to enrollment

07

Study locations

1 site
  • Childrens Center for Pulmonary and Allergic diseases, Aarhus University Hospital
    Aarhus N, 8200, Denmark
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized data that underlie the results reported in study articles (text, tables, figures, and appendices). The laws related to the handling of personal data will be followed and results are processed in accordance with the General Data Protection Regulation (GDPR) and the Danish Data Protection Act (Databeskyttelsesforordningen and Databeskyttelsesloven).

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: After the study has been finalized.

Access criteria: Researchers who provide a methodologically sound proposal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2027, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2024
First posted
Dec 24, 2024
StartActual
Apr 30, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms, verification date, oversight details and site details
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 4 other changes: index terms, verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06746077
Responsible party
Sune Rubak (Consultant, Associate Professor, Aarhus University Hospital) — Principal investigator
First posted
Dec 24, 2024
Start date
Apr 30, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion